Regular
NAV (25-Jul-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹120 Cr
Expense Ratio
2.37%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
-
Inception Date
06 Feb 2024
About this fund
As of 25-Jul-24, it has a Net Asset Value (NAV) of ₹11.25, Assets Under Management (AUM) of 119.57 Crores, and an expense ratio of 2.37%.
- WhiteOak Capital Pharma and Healthcare Fund Regular Growth has given a CAGR return of 12.47% since inception.
- The fund's asset allocation comprises around 91.44% in equities, 0.00% in debts, and 8.56% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Regular Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+12.47%
— (Cat Avg.)
Portfolio Summaryas of 30th June 2024
| Equity | ₹109.34 Cr | 91.44% |
| Others | ₹10.23 Cr | 8.56% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Cipla Ltd | Equity | ₹9.2 Cr | 7.69% |
| Torrent Pharmaceuticals Ltd | Equity | ₹7.23 Cr | 6.05% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹7 Cr | 5.86% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹6.93 Cr | 5.80% |
| Zydus Lifesciences Ltd | Equity | ₹6.6 Cr | 5.52% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹5.98 Cr | 5.00% |
| Divi's Laboratories Ltd | Equity | ₹5.02 Cr | 4.20% |
| Poly Medicure Ltd | Equity | ₹4.34 Cr | 3.63% |
| Mankind Pharma Ltd | Equity | ₹4.12 Cr | 3.45% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹4.11 Cr | 3.44% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹4.1 Cr | 3.43% |
| Ajanta Pharma Ltd | Equity | ₹4.03 Cr | 3.37% |
| Abbott India Ltd | Equity | ₹3.95 Cr | 3.31% |
| Biocon Ltd | Equity | ₹3.41 Cr | 2.85% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹3.34 Cr | 2.79% |
| Neuland Laboratories Limited | Equity | ₹2.96 Cr | 2.47% |
| Ami Organics Ltd | Equity | ₹2.63 Cr | 2.20% |
| Dr. Lal PathLabs Ltd | Equity | ₹2.44 Cr | 2.04% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.38 Cr | 1.99% |
| Piramal Pharma Ltd | Equity | ₹2.3 Cr | 1.93% |
| Shilpa Medicare Ltd | Equity | ₹2.25 Cr | 1.88% |
| Rainbow Childrens Medicare Ltd | Equity | ₹2.2 Cr | 1.84% |
| Gland Pharma Ltd | Equity | ₹2.16 Cr | 1.81% |
| FDC Ltd | Equity | ₹2.1 Cr | 1.76% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹1.91 Cr | 1.60% |
| RPG Life Sciences Ltd | Equity | ₹1.85 Cr | 1.55% |
| Gufic Biosciences Ltd | Equity | ₹1.71 Cr | 1.43% |
| AstraZeneca Pharma India Ltd | Equity | ₹1.4 Cr | 1.17% |
| Aurobindo Pharma Ltd | Equity | ₹1.39 Cr | 1.17% |
| Supriya Lifescience Ltd | Equity | ₹1.3 Cr | 1.09% |
| Innova Captab Ltd | Equity | ₹1.24 Cr | 1.04% |
| 182 DTB 22082024 | Bond - Gov't/Treasury | ₹1.24 Cr | 1.04% |
| Lupin Ltd | Equity | ₹1.11 Cr | 0.93% |
| Sanofi Consumer He | Equity | ₹1.08 Cr | 0.90% |
| Net Receivables / (Payables) | Cash | ₹0.97 Cr | 0.81% |
| Indegene Ltd | Equity | ₹0.97 Cr | 0.81% |
| Wockhardt Ltd | Equity | ₹0.92 Cr | 0.77% |
| Neogen Chemicals Ltd | Equity | ₹0.59 Cr | 0.50% |
| 91 DTB 08082024 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.42% |
| 91 DTB 26092024 | Bond - Gov't/Treasury | ₹0.49 Cr | 0.41% |
| India (Republic of) | Bond - Short-term Government Bills | ₹0.1 Cr | 0.08% |
Allocation By Market Cap (Equity)
Large Cap Stocks
26.38%
Mid Cap Stocks
28.23%
Small Cap Stocks
32.64%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹102.09 Cr | 85.38% |
| Basic Materials | ₹3.22 Cr | 2.69% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
Dheeresh Pathak
Since February 2024
Naitik Shah
Since April 2024
Additional Scheme Detailsas of 30th June 2024
ISIN | INF03VN01878 | Expense Ratio | 2.37% | Exit Load | - | Fund Size | ₹120 Cr | Age | 06 Feb 2024 | Lumpsum Minimum | ₹500 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Withdrawal within 1 year
Flat 15% tax on realised gains (STCG - short term capital gains)
Withdrawal after 1 year
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Regular Growth?
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Regular Growth?
Who manages the WhiteOak Capital Pharma and Healthcare Fund Regular Growth?
- Piyush Baranwal
- Ramesh Mantri
- Dheeresh Pathak
- Naitik Shah
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.